Viewmind

ViewMind's news and publications

From recent awards, new partnerships, and scientific publications to press releases and new content about the future of diagnostics and monitoring of neurocognitive disorders

We are excited to announce that ViewMind Inc. will present new results to identify frontotemporal dementia in the MCI stage (prodromal FTD) and to differentiate against Alzheimer’s disease in the MCI stage (prodromal AD).
Patients were tracked in a 4-year prospective study until the underlying causality of MCI was clinically diagnosed. This is based on ViewMind Inc.’s Atlas cognitive biomarker – using ocular digital phenotyping technology. Results will be presented on Sunday, July 16th, in Amsterdam at the Alzheimer’s Association® International Conference (AAIC2023).
Next
Mark email read

To be updated on ViewMind news please click buttons

Group 10694
Group 10695

To contact ViewMind

    Brain Health for Life
    Easy to perform. Non-invasive.

    Precision Neurology.

    Facebook-f Twitter Instagram

    Company Information

    General Links

    © Copyright Viewmind 2018 – 2024 | All rights reserved | Designed by SNTRIX

    Brain Health for Life
    Easy to perform. Non-invasive.

    Precision Neurology.

    Youtube Linkedin

    Company Information

    General Links

    Group 1075df9
    © Copyright Viewmind 2018 – 2025 | All rights reserved | Designed by SNTRIX

    This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    If you have questions about the interpretation of your results, please consult with your healthcare provider.